Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Align Technology, Inc. (ALGN) vs ResMed Inc. (RMD) Price & Performance

Align Technology, Inc.Trade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

Align Technology, Inc. vs ResMed Inc. — how do they compare? Align Technology, Inc. trades at $174.15 (market cap $12.29B), while ResMed Inc. trades at $226.31 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 2.7× Align Technology, Inc.'s market cap, and ResMed Inc. pays a 1.17% dividend while Align Technology, Inc. pays none. Which is the better fit depends on your goals.

ALGNRMD
Market Cap
$12.29B$32.61B
Sector
HealthHealth
52-Week High
$197.51$293.73
52-Week Low
$124.88$182.82
Enterprise Value
$11.30B$31.97B
Dividend Yield
1.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Align Technology, Inc.

ALGN trades at $173.4, down 1.5% today, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, a P/E of 30.03, and a net income margin of 9.99%. Recent news highlights a patent win in China and strategic initiatives under activist investor engagement, supporting its digital orthodontics leadership.

Outlook remains positive due to solid profitability and growth initiatives, but risks include competitive pressures and scanner segment weakness. Analyst consensus is strongly bullish with 73% buy ratings, viewing current valuation as attractive for long-term growth despite near-term technical headwinds.

ResMed Inc.

ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.

The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.

Returns comparison

Trailing returns across standard periods

About Align Technology, Inc.

Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).

Read more on ALGN

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD